Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsO

Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in adults with PsA. Effects of Temfya at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis and dactylitis was also seen through Week 100.  These data were presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference.

TRremfya is the first and only IL-23 inhibitor therapy approved in the US to treat both adults with active PsA and adults with moderate to severe plaque psoriasis (PsO).

"PsA can be a chronically painful and debilitating disease, and many PsA patients are still searching for enduring relief of their symptoms," says Philip J. Mease, MD, of the Swedish Medical Center/Providence St. Joseph Health and the University of Washington in Seattle, Washington and presenting author. "These data, which show that the observed benefits of Tremfya in PsA continue through two years, represent positive news for physicians and patients alike."   

Week 100 findings show that, among randomized patients, 76 percent of those receiving TREMFYA every four weeks and 74 percent of those receiving Tremfya every eight weeks achieved at least 20 percent improvement in the American College of Rheumatology (ACR 20) response criteria. Robust joint and skin response rates and mean improvements from baseline in outcome measures were maintained through two years, and approximately 90 percent of patients randomized to Tremfya continued treatment through Week 100. 

No new safety signals were observed in the safety analysis conducted through Week 112. Tremfya safety in patients with active PsA through two years was comparable to safety at six months and one year and generally consistent with Tremfya safety in patients with moderate to severe plaque PsO.

Among patients who had clinically meaningful PsO at baseline, 62 percent of patient receiving Tremfya every four weeks and 55 percent of those receiving Tremfya every eight weeks achieved complete skin clearance as measured by the Investigator Global Assessment (IGA) score of 0.